Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 1,729 · FY2023 0 · FY2024 0 — 3-yr total 1,729
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company imports and retails biological active food supplements and personal care products.
Subsidiary of Shezghuduli Pasukhismgeblobissazogadoeba Piluet Saipres Limited (100.0%)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 2,726 | 3,154 | 2,757 | 2,951 | 1,461 | 1,492 | 1,102 | -14.0% | |
| 12 | 262 | 160 | 2,264 | 1,742 | 730 | 332 | +74.5% | |
| TOTAL ASSETS | 2,738 | 3,415 | 2,917 | 5,215 | 3,203 | 2,222 | 1,434 | -10.2% |
| 1,323 | 1,642 | 1,289 | 1,784 | 2,115 | 2,621 | 1,091 | -3.2% | |
| 0 | 126 | 0 | 1,000 | 630 | 476 | 1,893 | +71.8% | |
| TOTAL LIABILITIES | 1,323 | 1,768 | 1,289 | 2,783 | 2,745 | 3,097 | 2,983 | +14.5% |
| 1,415 | 1,647 | 1,628 | 2,432 | 458 | 874 | 1,549 | nmf | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | ||||||||
| Total Debt | 0 | 255 | 144 | 288 | 266 | 754 | 1,962 | +50.4% |
| Cash & Equivalents | 1,340 | 1,959 | 1,503 | 181 | 280 | 248 | 215 | -26.3% |
| Net Debt | 1,340 | 1,704 | 1,358 | 107 | 14 | 506 | 1,747 | nmf |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →